ClinicalTrials.gg
Status unknownNCT02895191Updated Apr 20, 2018

The Safety and Dose Response Relationship of Ulinastatin for Acute Respiratory Distress Syndrome(ARDS)

A Phase 2 interventional study of ulinastatin and placebo in Acute Respiratory Distress Syndrome, sponsored by Techpool Bio-Pharma Co., Ltd.. Status unknown at 11 sites in China. Open to participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2018-04-20.

Sponsored by Techpool Bio-Pharma Co., Ltd. (part of Shanghai Pharmaceuticals Holding Co., Ltd) · Phase 2, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Apr 2018), so the status shown — last known as Enrolling by invitation — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years to 100 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 146 studies in Respiratory Distress Syndrome with a site in China — 54 open to participants now, 55 under way, 6 of them phase 3. Respiratory Distress Syndrome · China.

Planned enrollment
48th of 81
60 · median 100
Started
2016
with 2 others
Phase 2
7 of 146
2 open now
Registered
30th of 146
by date

Among the 146 studies in Respiratory Distress Syndrome with a site in China, this one is the 48th largest by planned enrollment of the 81 interventional ones that give a count, is one of 3 that started in 2016, is one of 7 in phase 2, and was the 30th registered.

Respiratory Distress Syndrome

1,387 studies on the registry are indexed under Respiratory Distress Syndrome; 282 are open to participants now.

Browse Respiratory Distress Syndrome studies →

Open to participants now

54 of the 146 studies in Respiratory Distress Syndrome with a site in China are open now. Recruiting first, the newest first:

49 more — sign in →

All 54 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 193 Respiratory Distress Syndrome studies recruiting now, 117 (61%) set no upper age limit and 48 (25%) stop at 75 or younger; 50 take children under 18; 9 take healthy volunteers.

This study: 18 Years to 100 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 146 studies in Respiratory Distress Syndrome with a site in China, or all of them as a file.
02

Study summary

Compared with placebo, evaluate the effects and safety of Ulinastatin(UTI) added to conventional treatment for ARDS; Evaluate the dose response relationship of Ulinastatin for ARDS.

Read the detailed description

After signed off the informed consent form by patient or surrogate, and after completing the screening phase, the patients who fulfill the inclusion and exclusion criteria will be randomized 1:1:1:1 to the 4 study arms. All the Patients will receive the study treatment drugs for 7 to 14 days. Use Day 28 of last patient as a cut-off day, Collect the follow up visit data on both Day 28 and Day 90 of other patients.

03

Conditions studied

  • Acute Respiratory Distress Syndrome
04

Who can participate

Ages eligible
18 Years to 100 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Have provided signed written form (ICF) from the patient or the patient's legal representative;
  2. Male or Female patients ≥18 years of age;
  3. ARDS defined with using 2012 Berlin Criteria;
  4. ARDS diagnosed ≤7 days, and patients should be mechanically ventilated(invasive and or noninvasive mechanical ventilation); 5)100mmhg \< PaO2/FiO2 \< 250mmhg with CPAP/PEEP≥5 cmH2O;

Exclusion criteria

Exclusion Criteria:

  1. Patient with known to Ulinastatin/adjuvant or patient with allergic constitution;
  2. Patients with artificial organs replacement therapy for liver or kidney;
  3. Glasgow Coma Scale (GCS)≤8;
  4. Cardiogenic pulmonary edema , and the cardiogenic pulmonary edema is as the only or primary reason for respiratory failure;
  5. ARDS caused by burning, drowning, poisoning;
  6. Presence of severe chronic liver diseases ( score 12-15),or severe chronic respiratory disease with a PaCO2 > 50 mmHg or the use of home oxygen;
  7. Neutrophils\<1.5×10\^9/L
  8. Moribund patients (i.e.,expected to live no longer than 24 hours) or with recent (within 7days or anytime during present hospitalization) cardiopulmonary arrest;
  9. Patients need long-term treatment or need to be treated with drugs;
  10. No intent/unwillingness to follow lung protective ventilation strategy or fluid management protocol;
  11. Lung transplant patients;
  12. Patients with , expected to live no longer than 6 months;
  13. Pregnant or breast-feeding;
  14. Patients who have participated in any clinical study within 3 months prior to the screening;
  15. Any condition that in the opinion of the investigator would add the patient's risk or jeopardize the operation of the study.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    Cohort 1

    Cohort 1- Ulinastatin 4.8 million units per day

    Drug: ulinastatin

  • Experimental
    Cohort 2

    Cohort 2- Ulinastatin 2.4 million units per day

    Drug: ulinastatin

  • Experimental
    Cohort 3

    Cohort 3- Ulinastatin 1.2 million units per day

    Drug: ulinastatin

  • Placebo comparator
    control group

    Placebo

    Drug: placebo

Interventions

  • Patients will receive the study drugs for 7 to 14 days

    Also known as: UTI, urinary trypsin inhibitor, bikunin

  • Drugplacebo

    Patients will receive the placebo for 7 to 14 days

06

What researchers measure

Primary outcomes

  1. The incidence of adverse events(AEs) which can not excluded relatedness with study Product

    Time frame: Day 1 to Day 90

Secondary outcomes

  1. Changes of PaO2/FiO2 ratio

    Time frame: Day 0 and Day 1 to within 24h after the last treatment

  2. Days alive and off ventilator

    Time frame: Day 1 to Day 28

  3. Days in the ICU

    Time frame: Day 1 to Day 14

  4. Changes of pulmonary compliance

    Time frame: Day 1 , Day 3 ,Day7 and within 24h after the last treatment

  5. Rate of new organ failure

    Time frame: Day 1 to Day 90

  6. Changes of APACHEⅡ Score from baseline

    Time frame: Day 3 ,Day7 and within 24h after the last treatment

  7. Changes of Murray Lung Injury Score from baseline

    Time frame: Day 3 ,Day7 and within 24h after the last treatment

  8. Changes of Sequential Organ Failure Assessment (SOFA) score from baseline

    Time frame: Day 3 ,Day7 and within 24h after the last treatment

  9. All-cause mortality

    Time frame: Day 28 , Day 90 and Day 1 to Day 14

07

Study locations

11 sites
  • The First Affiliated Hospital of Bengbu Medical College
    Bengbu, Anhui 233004, China
  • Beijing Anzhen Hospital, Capital Medical University
    Beijing, Beijing 100029, China
  • Guangzhou First People's Hospital
    Guangzhou, Guangdong 510180, China
  • First Affiliated Hospital of Guangzhou Medical University
    Guangzhou, Guangdong, China
  • Hainan General Hospital
    Haikou, Hainan 570311, China
  • Huadong Hospital,Fudan University
    Shanghai, Shanghai 200040, China
  • Shanghai Sixth People's Hospital
    Shanghai, Shanghia 200233, China
  • West China Hospital,Sichuan Unversity
    Chengdu, Sichuan 610041, China
  • The First Affiliated Hospital of Xinjiang Medical University
    Urumqi, Xinjiang 830054, China
  • Zhejiang Hospital
    Hangzhou, Zhejiang 310030, China
  • Lishui City People's Hospital
    Lishui, Zhejiang 323000, China
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2016, a primary completion of Sep 2019 and a completion of Dec 2019. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 21, 2016
First posted
Sep 9, 2016
Start
Aug 2016
Primary completionEst.
Sep 2019
CompletionEst.
Dec 2019
Last update
Apr 20, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 20, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02895191
Responsible party
Sponsor
First posted
Sep 9, 2016
Start date
Aug 2016
Primary completion
Sep 2019 (estimated)
Completion
Dec 2019 (estimated)
Last update
Apr 20, 2018

Study contacts

Yimin Li, Doctor
principal investigator · First Affiliated Hospital of Guangzhou Medical University

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Apr 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Urinastatin

Start the discussion